CRABP2 and non-small cell lung carcinoma: This study uncovers a novel CRABP2/PLAAT4-mediated lipid metabolic axis as the first reported mechanism driving NSCLC progression, where CRABP2 directly binds to PLAAT4 to decreases its protein stability, thereby enhancing lipid droplet accumulation and malignant phenotypes.